Most Clicked StoriesMore >


FDA releases equivalent of "Orange Book" for biosimilars

PCMA SmartBrief | Sep 10, 2014

The FDA has released the first edition of the "Purple Book," a list of biologic drugs and interchangeable biosimilars approved by the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research. The document, designed to be the equivalent of the "Orange Book," was created to help state health agencies, pharmacists and prescribers determine which biosimilars can be used in place of a specific biologic drug. Regulatory Focus (09/09) BioWorld (free content) (09/09)


N.Y. attorney general sues over switch to new drug

PCMA SmartBrief | Sep 16, 2014

Community pharmacies are at the center of prescription drug fraud

PCMA SmartBrief | Sep 12, 2014

Why the sky-high price for Genzyme's new Gaucher disease drug?

PCMA SmartBrief | Sep 10, 2014

Lack of FDA regulation on biosimilars means less savings

PCMA SmartBrief | Sep 15, 2014

Price of Gilead's next hep C drug to exceed Sovaldi's $84,000

PCMA SmartBrief | Sep 15, 2014

Growth in costs for employer-sponsored health plans slows

PCMA SmartBrief | Sep 10, 2014

Tiered pharmacy benefit plans remain popular

PCMA SmartBrief | Sep 16, 2014

Old insulin comes with hefty new price tag

PCMA SmartBrief | Sep 12, 2014

Cost savings from generic meds reach $239B in 2013

PCMA SmartBrief | Sep 11, 2014


Find PCMA SmartBrief Issues by Date:





Sign up for PCMA SmartBrief



Designed specifically for PBM industry professionals, PCMA SmartBrief is a FREE, daily e-mail newsletter. It provides the the most relevant and actionable PBM industry news in a quick, easy to read format. Learn more